The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...

Ultragenyx Pharmaceuticals RARE announced that the FDA has issued a Complete Response Letter (CRL) for its biologics license ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is one of the best low priced pharma stocks to buy now. On June 30, Rocket ...

Scientists from the Centenary Institute and the University of Sydney have made a landmark discovery that could lead to safer ...

The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...

A single shot of gene therapy restored hearing in people born deaf, with most showing improvement within weeks and some ...

The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat ...

Groundbreaking new research shows that it is possible to use gene therapy to restore hearing in both children and adults.

This is the first time such results have been achieved in both children and adult patients born with a specific type of ...

Nanoscope Therapeutics submitted the first modules of a biologics license application for MCO-010, an investigational gene ...

In his first 100 days as commissioner of the Food and Drug Administration, Marty Makary has made a handful of splashy ...